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ABSTRACT
Serum hepatitis B virus (HBV) DNA level is a predictor of the development of cirrhosis and hepatocellular
carcinoma in chronic hepatitis B patients. Nevertheless, the distribution of viral load levels in chronic HBV
patients in Brazil has yet to be described. This cross-sectional study included 564 participants selected in
nine Brazilian cities located in four of the five regions of the country using the database of a medical diag-
nostics company. Admission criteria included hepatitis B surface antigen seropositivity, availability of HBV
viral load samples and age ≥ 18 years. Males comprised 64.5% of the study population. Mean age was 43.7
years. Most individuals (62.1%) were seronegative for the hepatitis B e antigen (HBeAg). Median serum ALT
level was 34 U/L. In 58.5% of the patients HBV-DNA levels ranged from 300 to 99,999 copies/mL; however, in
21.6% levels were undetectable. Median HBV-DNA level was 2,351 copies/mL. Over 60% of the patients who
tested negative for HBeAg and in whom ALT level was less than 1.5 times the upper limit of the normal ran-
ge had HBV-DNA levels > 2,000 IU/mL, which has been considered a cut-off point for indicating a liver biop-
sy and/or treatment. In conclusion, HBV-DNA level identified a significant proportion of Brazilian individuals
with chronic hepatitis B at risk of disease progression. Furthermore, this tool enables those individuals
with high HBV-DNA levels who are susceptible to disease progression to be identified among patients with
normal or slightly elevated ALT.
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ORIGINAL ARTICLE
INTRODUCTION
Despite the fact that chronic hepatitis B (CHB)
is a preventable disease, more than 2 billion people
around the world are infected with the hepatitis B
virus (HBV) and more than 350 million people
have chronic hepatitis B.1 Patients with chronic
hepatitis B are at an increased risk of developing
cirrhosis of the liver and hepatocellular carcinoma
(HCC).2 Moreover, there is recent evidence indica-
ting a relationship between the development of the-
se complications and baseline HBV-DNA level.3,4
With regard to progression to cirrhosis, the Risk
Evaluation of Viral Load Elevation and Associated
Liver Disease/Cancer-Hepatitis B Virus (REVEAL-
HBV) study found that the cumulative incidence of
liver cirrhosis increased as a function of HBV-DNA
levels, ranging from approximately 5% when viral
load was undetectable (< 300 copies/mL) to 36%
with ≥ 106 copies/mL irrespective of alanine amino-
transferase (ALT) or hepatitis B e antigen (HBeAg)
status.3 Similar results have been reported with
respect to the risk of developing hepatocellular car-
cinoma. Cumulative incidences were 1.3% with <
300 copies/mL and 14.9% with ≥ 106 copies/mL.
HBV-DNA levels were significantly associated with
the risk of developing hepatocellular carcinoma (p
< 0.001).4
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The true prevalence of CHB in Brazil is unk-
nown. Data from the Brazilian Ministry of Health
indicate that at least 1% of the population is chroni-
cally infected with HBV,5 particularly in the major
urban areas; however, there is a distinct risk of un-
derestimation. Many regional studies have been ca-
rried out to evaluate the prevalence of the disease,
but none on a nationwide scale.6-9 The majority of
these findings are derived from studies conducted in
small communities, specific population groups or
blood-bank samples.10-14 These studies indicate that
there are areas of high endemicity in which the pre-
valence of chronically ill hepatitis B patients ranges
from 8% to 25%, while the prevalence of anti-HBs
positivity is 60-85%. The areas in which prevalence
is higher are typically found in the Amazon region
in the north of the country. Areas with intermediate
HBV prevalence in which the rate of chronic carria-
ge ranges from 2% to 7% are located in the western
part of the state of Santa Catarina and in southwest
Paraná in the south of the country and in the state
of Espírito Santo in the southeastern region of Bra-
zil. Finally, most of the regions of the country, in-
cluding the state capital cities, are known to be
areas of low endemicity in which the prevalence of
chronic patients is below 2% (Figure 1). In contrast
with the genotypes identified in Asian countries, A,
D and F are the genotypes most frequently found in
Brazil, with other genotypes only rarely being des-
cribed.
The aim of this study was to evaluate viral load
levels in serum samples of Brazilian patients diagno-
sed with chronic hepatitis B. Secondary objectives
were to assess ALT levels and HBeAg status, strati-
fied according to the different serum HBV-DNA le-
vels.
METHODS
Study subjects and laboratory tests
Diagnósticos da América (DASA) is a private me-
dical diagnostics company with branches in all the
major urban areas of Brazil with the exception of
the northern region: in the south (in the state
of Paraná), in the southeast (in São Paulo and Rio de
Janeiro), in the northeast (in the state of Ceará)
and in the Midwest (in the state of Goiás and in
Brasilia, the Federal District). DASA receives sam-
ples from patients with private health insurance
(about 30% of the Brazilian population has access to
private health insurance) and is not a service provi-
der for the public healthcare system. In the present
study, the DASA database was used to analyze the
results of samples collected between July and Dec-
ember 2007 as part of the routine evaluation of CHB
patients. Of the samples analyzed, measurements
were performed on the same day in 510 cases, while
the samples from the remaining 54 patients were
analyzed within 1 month of HBV viral load sam-
pling. When several samples were available for the
same patient, the first available result was selected.
This diagnostics company does not register any data
regarding treatment. Eligibility criteria included age
≥ 18 years, hepatitis B (HBsAg positive) diagnosed
more than six months previously, and availability of
HBV-DNA samples. The study was approved by the
Institutional Review Board of the Heliópolis Hospi-
tal, São Paulo, Brazil.
Demographic information obtained with respect
to the patients included age, gender, city and region
of origin, and ethnicity. Serological tests included
ALT (alanine aminotransferase) and AST (aspartate
aminotransferase) performed using enzyme immu-
noassay (Synemed, Benicia, US); HBsAg, HBeAg
and HBeAb performed by chemiluminescence (Abbo-
tt Laboratories, North Chicago, IL); and viral DNA
detected using real-time polymerase chain reaction
(RT-PCR) and validated with a commercially appro-
ved RT-PCR - TaqMan® (Roche) with intra and in-
ter-assay ranges within acceptable limits. With this
technique, a fluorescent signal is detected each time
a copy of DNA is synthesized. The absolute quanti-
fication of the sample is compared to a standard cur-
ve in each assay. The methodology sensitivity is 75
copies/mL and linearity is between 75 and
75,000,000 copies/mL. The equipment used was an
Applied Biosystems Real time PCR: SDS 7000/7500/
7500 fast (Applied Biosystems, Foster City, CA,
USA). The College of American Pathologists (CAP)Figure 1. Missing
Missing figure (we dont received)
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proficiency assay is performed every 4 months and
the Clinical Laboratory Accreditation Program
(Programa de Acreditação para Laboratórios Clínico
- PALC) is completed every 3 months as DASAs
quality control standard. All tests were performed in
local facilities with the exception of HBV-DNA, whi-
ch was performed at a central laboratory.
A subset analysis was carried out in which the
clinically significant15 level of HBV replication was
defined as a viral load of 10,000 copies/mL (approxi-
mately 2,000 IU/mL), reflecting a consequently high
risk of developing liver complications. In this group
of patients, the relationship between different HBV-
DNA levels and HBeAg status and ALT levels was
analyzed.
Statistical analysis
Findings were described as measures of central
tendency and variability. Comparisons between
means were performed using the t-test or Mann-
Whitney test, according to the underlying distribu-
tion of the variables. The relationships between
HBV-DNA level (DNA copies/mL), ALT (IU/L) level,
gender and HBeAg were assessed using analysis of
variance (ANOVA) with rank transformation for
HBV-DNA level as a continuous variable and the
chi-square test for HBV-DNA as a categorical varia-
ble (categories defined as < 300 (undetectable); 300-
9,999; 10,000-99,999; 100,000-999,999; and ≥ 1
million). Both ALT (normal, defined according to
gender as 10-40 IU/L for males and 7-35 IU/L for fe-
males versus abnormal, defined as any value outside
the normal range) and HBeAg (negative versus posi-
tive) were categorized for analysis. Missing values
for these variables were not considered in the analy-
sis. In all cases, the level of statistical significance
was set at 0.05 (two-tailed).
RESULTS
Study population
A total of 2,050 consecutive patients who had tes-
ted positive for HBsAg were considered for this stu-
dy. Of these, 27% (564) individuals were eligible for
inclusion. The baseline characteristics and the dis-
tribution of serum HBV-DNA levels at admission to
the study are shown in Table 1. In 122 study partici-
pants (21.6%), HBV-DNA levels were undetectable
(< 300 copies/mL), while 112 participants (19.8%)
had a level ≥ 100,000 copies/mL. No statistically sig-
nificant correlation was found between HBV-DNA
levels and the patients place of origin; however, fe-
males had lower HBV-DNA levels (median 1472.5)
compared to males (median 2815), p < 0.0001.
HBeAg-positive patients had significantly higher
ALT levels (mean 170.3 ± 391 IU/L) compared to
HBeAg-negative patients (mean 53.9 ± 169.4 IU/L),
Table 1. Baseline characteristics of the 564 chronic hepatitis
B patients comprising the study sample.
Characteristic N(%)
Age (years)
Mean ± SD* 43.7 ± 12.3
Median 43




Region of origin (state)
Northeast (Ceará) 37 (7%)
Midwest (Federal District) 34 (6%)
Midwest (Goiás) 30 (5%)
South (Paraná) 34 (6%)
Southeast (Rio de Janeiro) 146 (26%)
Southeast (São Paulo) 283 (50%)
HBV-DNA (copies/mL)
Mean ± SD 59,868,389 ± 407,712,275
Median 2,351
Range 65 - 7,849,999,872
Undetectable 122 (21.6%)
300 - 9,999 259 (45.9%)
10,000 - 99,999 71 (12.6%)
100,000 - 999,999 29 (5.1%)
≥ 1million 83 (14.7%)
ALT (IU/L)#
Mean ± SD 67.7 ± 201.8
Median 34





Mean ± SD 43.7 ± 88.9
Median 29








* SD: Standard Desviation. ALT: Alanine transaminase. AST: Aspartate
transaminase. HbeAg: Hepatitis B e antigen. HBV: Hepatitis B virus.
# Normal values: ALT: Males: 10-40 U/L; Females: 7 - 35 U/L; AST: Males:
15 - 40 U/L; Females: 13 - 35 U/L.
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p < 0.0001 (Table 2). HBV-DNA levels were signifi-
cantly higher in HBeAg-positive individuals and in
those with elevated ALT levels compared to HBeAg-
negative patients and those with normal ALT levels
(p < 0.0001 for both comparisons) (Table 3).
Subset analyses of individuals with clinically sig-
nificant15 HBV-DNA levels (≥ 10,000 copies/mL),
stratified according to whether or not ALT values
were less than 1.5 times the ULN (upper limit of the
normal range), are shown for the combined group of
HBeAgpositive and HBeAg-negative patients toge-
ther (Table 4) and for HBeAg-negative patients alo-
ne (Table 5). Analysis showed that 63.2% of HBeAg-
negative patients with HBV-DNA levels > 10,000
copies/mL had ALT levels less than 1.5 times the
ULN (Table 5).
DISCUSSION
This study provides a cross-sectional view of
CHB in selected regions of Brazil, a country in whi-
ch approximately 2 million people are estimated to
Table 4. Relationship between HBV-DNA and ALT levels (the combined group of HBeAg-positive and negative patients together).
HBV-DNA (DNA copies/mL) ALT ≤ 1.5X ULN ALT > 1.5X ULN Total
10,000 - 100,000 30 (33.7%) 7 (7.9%) 37 (41.6%)
> 100,000 18 (20.2%) 34 (38.2%) 52 (58.4%)
Total 48 (53.9%) 41 (46.1%) 89 (100%)
P-value < 0.0001.
Table 5. Relationship between HBV-DNA and ALT levels in HBeAg-negative patients.
HBV-DNA (DNA copies/mL) ALT ≤ 1.5X ULN ALT >1.5X ULN Total
10,000 to 100,000 30 (39.5%) 5 (6.6%) 35 (46.1%)
> 100,000 18 (23.7%) 23 (30.3%) 41 (53.9%)
Total 48 (63.2%) 28 (36.8%) 76 (100%)
P-value = 0.0002
ALT: Alanine transaminase. HbeAg: Hepatitis B e antigen. HBV: Hepatitis B virus.
Table 2. ALT levels according to HBeAg status.
Characteristics ALT (IU/L)
N Mean ± SD Median p-value*
HbeAg
Negative 295 53.9 ± 169.4 33 <0.0001
Positive 60 170.3 ± 391 55
HbeAg: Hepatitis B e antigen.
Table 3. HBV-DNA levels according to HBeAg status and ALT categories.
Characteristics HBV-DNA (DNA copies/mL)
N Mean ± SD Median P-value
HBeAg
Negative 350 23,800,970 ± 152,158,336 1,789 < 0.0001
Positive 63 343,094,176 ± 1,110,062,023 72,924
ALT (IU/L)*
Normal 266 14,563,884 ± 173,076,480 985 < 0.0001
Abnormal 193 149,705,616 ± 657,935,892 19,226
ALT: Alanine transaminase. HbeAg: Hepatitis B e antigen. HBV: Hepatitis B virus. *Normal values: ALT: Males: 10 - 40 U/L; Females: 7 - 35 U/L.
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be HBV carriers.5 Although in some areas of Brazil,
such as the western Amazon basin, prevalence rates
are as high as 16%,16 endemicity in the country as a
whole is considered intermediate, ranging from 1%
to 8%.8,17
The primary objective of this study was to identi-
fy the distribution of viral load levels in Brazilian
CHB patients living in six states which, together,
contain almost half the countrys total population.18
HBV-DNA levels were undetectable in 21.6% of par-
ticipants, while 58.5% had levels ranging from 300
to 99,999 copies/mL and 19.8% had levels ≥ 100,000
copies/mL. More importantly, the present study de-
monstrates that the viral load levels in Brazilian
CHB patients are comparable to those described in
studies conducted in Taiwan3,4 in which HBV-DNA
levels were undetectable in 23.9% of study partici-
pants, while 26.7% had levels ≥ 100,000 copies/mL.
Nevertheless, it is difficult to compare the present
study with these other earlier studies due to the di-
fferences in HBV genotypes between Asia and Latin
America. In agreement with current literature,3,4 in
the present study viral load levels were lower in the
population of HBeAg-negative patients compared to
the HBeAg-positive patients, patients with abnor-
mal ALT levels usually having a higher viral load le-
vel.
The present study also assessed the relationship
between HBV-DNA levels and ALT levels and HBe-
Ag status. In accordance with previous reports on
ALT and HbeAg,19,20 this study has shown that
HBV-DNA levels are significantly higher in HBeAg-
positive individuals and in those with abnormal ALT
levels. HBeAg was positive in 15.3% of individuals
for whom these results were available, a proportion
that is almost identical to that observed in the RE-
VEAL-HBV study. In the latter study, individuals
were seronegative for antibodies against the hepati-
tis C virus at study entry; on the other hand, no
data regarding hepatitis C virus antibodies were
available in the present study, which precludes eva-
luation of a possible role of a comorbid hepatitis C
infection as a factor contributing to liver damage.
Furthermore, it is conceivable that ALT levels in
the Brazilian patients included in this study reflec-
ted the absence of antiviral treatment in many ca-
ses, since information on such treatment was
unavailable.
Current hepatitis B treatment guidelines genera-
lly recommend no treatment for HBeAg-negative pa-
tients with normal or only slightly elevated ALT
levels (i.e. ≤ twice the ULN), since they are not con-
sidered to have the active disease.21
However, when our subset analysis focused on
such individuals, a relatively large proportion was
found to have HBV-DNA levels > 10,000 copies/mL.
This threshold was used since the effect of treat-
ment in this population is unknown, making it im-
possible to distinguish those patients in whom low
HBV-DNA levels are a result of therapy and sero-
conversion from those patients in whom the disease
is inactive. By excluding those individuals with low
viral load levels from this analysis, our objective
was to assess the prevalence of a high viral load and
to evaluate ALT, since it would be expected that
most patients with high ALT levels would have the
active disease.22,23
In Brazil, tests for the evaluation of HBV-DNA le-
vels are not generally available within the public
healthcare system; therefore, in HBeAg-negative pa-
tients with normal ALT levels the disease may be
wrongly classified as inactive. Consequently, the cli-
nical follow-up of these patients will not include li-
ver biopsy or any form of treatment. This study
identified a number of patients with this profile and
it is probable that patients in similar conditions
would be missed within the public healthcare sys-
tem, in which HBV-DNA testing is not routinely
performed. Furthermore, in the absence of serial
HBV-DNA measurement, physicians caring for CHB
HBeAg-negative patients may find it difficult to deci-
de when to perform biopsy and/or initiate antiviral
therapy. Furthermore, studies published in the lite-
rature24,26 report that patients with elevated HBV-
DNA levels are more prone to disease progression.
For example, Yuen, et al. showed that age, gender,
core promoter mutation, HBV-DNA and cirrhosis,
but not ALT levels, are predictive of the develop-
ment of HCC. Nevertheless, Feld, et al. carried out
a prospective study and showed that HBV-DNA le-
vels > 10,000 copies/mL in HBeAg-negative patients
with normal ALT levels was a relevant predictor of
elevated ALT levels at future follow-up visits.22,27
Considering the evidence that viral load levels >
10,000 copies/mL are associated with an increasing
probability of cirrhosis of the liver3 and HCC,4,18,24
we believe that there is growing evidence that pa-
tients with high HBV-DNA levels and low ALT le-
vels should be considered to be harboring the active
infection and to be at an increased risk of complica-
tions. These patients, therefore, demand to be follo-
wed-up more closely.
There are some potential limitations to the pre-
sent study that should be taken into consideration,
such as the uncertainty with respect to how repre-
sentative the sample is of the population of inter-
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est, namely all individuals with CHB in the six sta-
tes participating in this study and, more broadly,
in Brazil as a whole. Although DASA is one of the
largest medical diagnostics companies in the coun-
try, its presence covering an area that is both geo-
graphically large and densely populated, access to
healthcare in Brazil is unevenly distributed
through the various socioeconomic strata of the po-
pulation. The patients using the facilities of this la-
boratory tend to be individuals of middle to high
socioeconomic class who have access to private
healthcare. It is, therefore, possible that health-re-
lated habits, body weight and access to treatment
are different from those of patients in the Amazon
region, the area in which HBV is most endemic.
Nevertheless, some endemic areas are located in
the southeastern and southern regions of the coun-
try and patients there may more closely resemble
the patients enrolled in this present study. Ano-
ther important limitation is the lack of information
regarding any therapy administered to these pa-
tients. While some measures were taken to identify
treatment-naive patients in the database and since
analysis of the subset of patients with > 10,000 co-
pies/mL was also aimed at excluding those patients
with low viral loads probably indicative of ongoing
treatment, it is impossible, however, to guarantee
the treatment status of patients and to be certain
whether viral load levels are a consequence of the
disease or the treatment.
Despite the potential limitations outlined abo-
ve, the database used in this study offered an uni-
que opportunity to evaluate several aspects of
chronic hepatitis B in Brazil. Furthermore, corre-
lating this data with various papers published in
the literature on the evaluation of HBV-DNA le-
vels and disease progression3,4,24-26 may provide at
least a rough estimate regarding the risk of pro-
gression to HCC in this Brazilian sample of chro-
nic HBV patients, provided other differences such
as age, ethnicity, genotype and the lack of data re-
garding antiviral treatment, among other issues,
are taken into account. The advent of new, effecti-
ve therapies for HBV has provided the physician
treating these patients with a greater possibility
of controlling the disease in many HBV-infected
patients. The findings of the present study may
contribute towards further studies designed to re-
ach a better definition of the population at risk
and may help increase awareness with respect to
the prevalence of the principal factors that seem
to affect the risk of disease progression in the Bra-
zilian population.
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 HBV: Hepatitis B Virus.
 HBeAg: Hepatitis B e Antigen.
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 HCC: Hepatocellular carcinoma.
 DASA: Diagnósticos da América.
 AST: Aspartate aminotransferase.
 RT-PCR: Real-time polymerase chain reaction.
 ULN: Upper limit of the normal range.
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